Metastatic hormone-sensitive and castration resistant prostate cancer registry: CAPRI 3.0

Recruiting

• Conditions: Metastatic hormone-sensitive and castration resistant prostate cancer.

• Registration Number: NL-OMON24783
• Lead Sponsor: Radboud University Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 10000

Inclusion Criteria

Patients who were treated in a participating hospital after 01-01-2016 and have:
- metastatic HSPC, defined as involvement of lymph nodes, bones or viscera on radiological assessment or as defined by either the treating doctor/physician (i.e. palliative treatment with surgical or medical castration)
- metastatic CRPC, defined by the treating doctor/physician or the definition of the European Urology Association (EAU)[10], as prostate cancer that is progressing despite medical or surgical castration (i.e. castrate levels of testosterone (= 50 ng/dL or <1.7 nmol/L)

Exclusion Criteria

None.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The main objective is to assess effectiveness, efficiency and quality of treatments in HSPC and CRPC patients in the Netherlands.

Secondary Outcome Measures

Name	Time	Method
-To describe the population of HSPC and CRPC patients;<br>-To assess treatment patterns and outcomes of systemic anti-cancer treatment in HSPC and CRPC;<br>-Focus on systemic treatment (including hormonal therapy, chemotherapy, bone directed therapy, immunotherapy, targeted therapy), radiotherapy, radionuclides and surgery;<br>-Focus on relevant and readily available outcomes (including overall survival, treatment duration, biochemical response, severe adverse events);<br>-To assess guideline adherence of diagnostic evaluation and anti-cancer treatment;<br>-To assess access of patients to treatment innovations, mainly clinical trials and new treatment options;<br>-To evaluate differences in real-world populations and trial populations.